Week In Review: Taiwan Liposome Files For $50 Million Secondary IPO In The U.S.

Taiwan Liposome (Pending:TLC) (TW:4152), a company developing extended-release delivery of known drugs, filed for a $50 million IPO on the NASDAQ exchange (see story). The company is already listed in Taiwan, where it has a market capitalization of $198 …
( read original story …)